Zeng J - Search Results

1

Targeting silibinin in the antiproliferative pathway.

Li L, Zeng J, Gao Y, He D. Li L, et al. Among authors: zeng j. Expert Opin Investig Drugs. 2010 Feb;19(2):243-55. doi: 10.1517/13543780903533631. Expert Opin Investig Drugs. 2010. PMID: 20047507 Review.

2

Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma.

Li L, Gao Y, Zhang L, Zeng J, He D, Sun Y. Li L, et al. Among authors: zeng j. Cancer Lett. 2008 Dec 8;272(1):61-9. doi: 10.1016/j.canlet.2008.06.033. Epub 2008 Aug 23. Cancer Lett. 2008. PMID: 18723275

3

[Expression of Smad4 in prostate cancer LNCaP and ARCaP cell lines with different metastatic potentials and its significance].

Wu KJ, Zhang D, Zhu GF, Cheng HP, Zeng J, Zhang LL, Wang XY, He DL. Wu KJ, et al. Among authors: zeng j. Zhonghua Nan Ke Xue. 2009 Jan;15(1):41-4. Zhonghua Nan Ke Xue. 2009. PMID: 19288748 Chinese.

4

Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression.

Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D, Li L, Fan JH, Wang XY, He DL. Wu KJ, et al. Among authors: zeng j. Acta Pharmacol Sin. 2009 Aug;30(8):1162-8. doi: 10.1038/aps.2009.94. Epub 2009 Jul 6. Acta Pharmacol Sin. 2009. PMID: 19578386 Free PMC article.

5

[High-dose estrogen inhibits prostate development by down-regulating SHH signaling in new-born SD rats].

Yang ZL, Zhu GD, Zeng J, Zhang G, Wang XY, He DL. Yang ZL, et al. Among authors: zeng j. Zhonghua Nan Ke Xue. 2009 Jul;15(7):612-6. Zhonghua Nan Ke Xue. 2009. PMID: 19694374 Chinese.

6

Upregulation of human DNA binding protein A (dbpA) in gastric cancer cells.

Wang GR, Zheng Y, Che XM, Wang XY, Zhao JH, Wu KJ, Zeng J, Pan CE, He DL. Wang GR, et al. Among authors: zeng j. Acta Pharmacol Sin. 2009 Oct;30(10):1436-42. doi: 10.1038/aps.2009.137. Epub 2009 Sep 14. Acta Pharmacol Sin. 2009. PMID: 19749785 Free PMC article.

7

[Identification of TGF-beta/Smads pathway in human prostate cancer cell lines and its significance].

Wu KJ, Zhu GF, Zhang D, Zeng J, Wang XY, Xue Y, Zhang LL, He DL. Wu KJ, et al. Among authors: zeng j. Zhonghua Nan Ke Xue. 2009 Oct;15(10):920-4. Zhonghua Nan Ke Xue. 2009. PMID: 20112742 Chinese.

8

[Comparison of transcription factors repressing epithelial phenotype in two different prostate cancer EMT models and its significance].

Wu KJ, Zeng J, Zhu GD, Zhang D, Xue Y, Chen YL, Wang XY, He DL. Wu KJ, et al. Among authors: zeng j. Zhonghua Nan Ke Xue. 2010 Feb;16(2):137-41. Zhonghua Nan Ke Xue. 2010. PMID: 20369697 Chinese.

9

Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors.

Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, Zhu G, Yang L, Wang X, He D. Wu K, et al. Among authors: zeng j. Oncol Rep. 2010 Jun;23(6):1545-52. Oncol Rep. 2010. PMID: 20428808

10

Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth.

Xue Y, Li L, Zhang D, Wu K, Guo P, Zeng J, Wang X, He D. Xue Y, et al. Among authors: zeng j. Oncol Rep. 2010 Dec;24(6):1551-9. doi: 10.3892/or_00001017. Oncol Rep. 2010. PMID: 21042751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results